IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v607y2022i7918d10.1038_s41586-022-04865-0.html
   My bibliography  Save this article

Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination

Author

Listed:
  • Rahul K. Suryawanshi

    (Gladstone Institutes)

  • Irene P. Chen

    (Gladstone Institutes
    University of California, San Francisco
    University of California, San Francisco
    University of California, San Francisco)

  • Tongcui Ma

    (Gladstone Institutes
    UCSF-Abbott Viral Diagnostics and Discovery Center)

  • Abdullah M. Syed

    (Gladstone Institutes
    University of California, Berkeley)

  • Noah Brazer

    (University of California, San Francisco)

  • Prachi Saldhi

    (University of California, San Francisco)

  • Camille R. Simoneau

    (Gladstone Institutes
    University of California, San Francisco
    University of California, San Francisco)

  • Alison Ciling

    (Gladstone Institutes
    University of California, Berkeley)

  • Mir M. Khalid

    (Gladstone Institutes)

  • Bharath Sreekumar

    (Gladstone Institutes)

  • Pei-Yi Chen

    (Gladstone Institutes)

  • G. Renuka Kumar

    (Gladstone Institutes)

  • Mauricio Montano

    (Gladstone Institutes
    Michael Hulton Center for HIV Cure Research at Gladstone)

  • Ronne Gascon

    (Gladstone Institutes)

  • Chia-Lin Tsou

    (Gladstone Institutes)

  • Miguel A. Garcia-Knight

    (University of California, San Francisco)

  • Alicia Sotomayor-Gonzalez

    (University of California, San Francisco)

  • Venice Servellita

    (University of California, San Francisco)

  • Amelia Gliwa

    (University of California, San Francisco)

  • Jenny Nguyen

    (University of California, San Francisco)

  • Ines Silva

    (Curative Inc.)

  • Bilal Milbes

    (Curative Inc.)

  • Noah Kojima

    (University of California, Los Angeles)

  • Victoria Hess

    (Curative Inc.)

  • Maria Shacreaw

    (Curative Inc.)

  • Lauren Lopez

    (Curative Inc.)

  • Matthew Brobeck

    (Curative Inc.)

  • Fred Turner

    (Curative Inc.)

  • Frank W. Soveg

    (Gladstone Institutes)

  • Ashley F. George

    (Gladstone Institutes
    University of California, San Francisco)

  • Xiaohui Fang

    (University of California, San Francisco
    University of California, San Francisco)

  • Mazharul Maishan

    (University of California, San Francisco
    University of California, San Francisco)

  • Michael Matthay

    (University of California, San Francisco
    University of California, San Francisco)

  • Mary Kate Morris

    (California Department of Public Health)

  • Debra Wadford

    (California Department of Public Health)

  • Carl Hanson

    (California Department of Public Health)

  • Warner C. Greene

    (Gladstone Institutes
    University of California, San Francisco
    Michael Hulton Center for HIV Cure Research at Gladstone
    University of California, San Francisco)

  • Raul Andino

    (University of California, San Francisco)

  • Lee Spraggon

    (Curative Inc.)

  • Nadia R. Roan

    (Gladstone Institutes
    University of California, San Francisco)

  • Charles Y. Chiu

    (University of California, San Francisco
    UCSF-Abbott Viral Diagnostics and Discovery Center
    University of California, Berkeley
    University of California, San Francisco)

  • Jennifer A. Doudna

    (Gladstone Institutes
    University of California, Berkeley
    University of California, Berkeley
    Lawrence Berkeley National Laboratory)

  • Melanie Ott

    (Gladstone Institutes
    University of California, San Francisco
    University of California, San Francisco
    Chan Zuckerberg Biohub)

Abstract

SARS-CoV-2 Delta and Omicron are globally relevant variants of concern. Although individuals infected with Delta are at risk of developing severe lung disease, infection with Omicron often causes milder symptoms, especially in vaccinated individuals1,2. The question arises of whether widespread Omicron infections could lead to future cross-variant protection, accelerating the end of the pandemic. Here we show that without vaccination, infection with Omicron induces a limited humoral immune response in mice and humans. Sera from mice overexpressing the human ACE2 receptor and infected with Omicron neutralize only Omicron, but not other variants of concern, whereas broader cross-variant neutralization was observed after WA1 and Delta infections. Unlike WA1 and Delta, Omicron replicates to low levels in the lungs and brains of infected animals, leading to mild disease with reduced expression of pro-inflammatory cytokines and diminished activation of lung-resident T cells. Sera from individuals who were unvaccinated and infected with Omicron show the same limited neutralization of only Omicron itself. By contrast, Omicron breakthrough infections induce overall higher neutralization titres against all variants of concern. Our results demonstrate that Omicron infection enhances pre-existing immunity elicited by vaccines but, on its own, may not confer broad protection against non-Omicron variants in unvaccinated individuals.

Suggested Citation

  • Rahul K. Suryawanshi & Irene P. Chen & Tongcui Ma & Abdullah M. Syed & Noah Brazer & Prachi Saldhi & Camille R. Simoneau & Alison Ciling & Mir M. Khalid & Bharath Sreekumar & Pei-Yi Chen & G. Renuka K, 2022. "Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination," Nature, Nature, vol. 607(7918), pages 351-355, July.
  • Handle: RePEc:nat:nature:v:607:y:2022:i:7918:d:10.1038_s41586-022-04865-0
    DOI: 10.1038/s41586-022-04865-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-022-04865-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1038/s41586-022-04865-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ahumada, M. & Ledesma-Araujo, A. & Gordillo, L. & MarĂ­n, J.F., 2023. "Mutation and SARS-CoV-2 strain competition under vaccination in a modified SIR model," Chaos, Solitons & Fractals, Elsevier, vol. 166(C).
    2. Cai He & Jingyun Yang & Weiqi Hong & Zimin Chen & Dandan Peng & Hong Lei & Aqu Alu & Xuemei He & Zhenfei Bi & Xiaohua Jiang & Guowen Jia & Yun Yang & Yanan Zhou & Wenhai Yu & Cong Tang & Qing Huang & , 2022. "A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    3. Zheng Quan Toh & Nadia Mazarakis & Jill Nguyen & Rachel A. Higgins & Jeremy Anderson & Lien Anh Ha Do & David P. Burgner & Nigel Curtis & Andrew C. Steer & Kim Mulholland & Nigel W. Crawford & Shidan , 2022. "Comparison of antibody responses to SARS-CoV-2 variants in Australian children," Nature Communications, Nature, vol. 13(1), pages 1-5, December.
    4. Lorena M. Coria & Juan Manuel Rodriguez & Agostina Demaria & Laura A. Bruno & Mayra Rios Medrano & Celeste Pueblas Castro & Eliana F. Castro & Sabrina A. Del Priore & Andres C. Hernando Insua & Ingrid, 2024. "A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    5. Saranya Sridhar & Roman M. Chicz & William Warren & Jim Tartaglia & Stephen Savarino & Sanjay Gurunathan & Jean-Francois Toussaint, 2022. "The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022," Nature Communications, Nature, vol. 13(1), pages 1-3, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:607:y:2022:i:7918:d:10.1038_s41586-022-04865-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.